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Abstract
The Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a
collaborative venture that brings together interventional cardiologists, administrative
partners, and select members of the cardiovascular industry community annually for
high-level field-wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart
disease. Each session was moderated by a senior content expert and co-moderated
by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance
participation in this discussion, create additional dialog from a broader base, and
thereby aid SCAI, the industry community and external stakeholders in developing
specific action items to move these areas forward.
KEYWORDS

congenital heart disease, coronary artery disease, pediatrics, peripheral arterial disease,
structural heart disease intervention
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I N T RO DU CT I O N

The annual Society for Cardiovascular Angiography and Interventions
(SCAI) Think Tank brings together content experts, SCAI leaders, and key
industry partners for a one-day session on timely topics within the four
pillars of interventional cardiology—coronary, peripheral, structural, and

2 | CORONARY: PERCUTANEOUS
CORONARY PROCEDURES IN THE
A M BU L A T O R Y S U RG E R Y C EN T E R— W H A T
DO ES TH IS ME AN TO T H E P RAC TI CE ,
OVERSIGHT, VALUE, AND QUALITY OF
PROCEDURAL AREAS?

congenital. The themes of this year centered on quality assurance of coronary and peripheral procedures, either at ambulatory surgical centers or

Over the last 35 years, percutaneous coronary intervention (PCI) has

in the hospital setting, the need to expand indications for minimally inva-

evolved considerably in terms of device technology, pharmacologic

sive structural procedures to meet the needs of an aging cardiovascular

options, and procedural techniques. In parallel with these scientific

population, and the need to track implantable devices over time in our

advancements by our members and industry partners, the rates of

pediatric patients with congenital heart disease (CHD) who have now

PCI-related complications have dropped precipitously despite the

been able to achieve a longer life expectancy into young adulthood, mid-

increasing anatomic and clinical complexity seen more routinely now

dle age, and beyond. It is hoped that these discussions stimulate further

in patients presenting with coronary artery disease.1,2 Accordingly,

initiatives within SCAI, our members, and our industry colleagues to

same-day discharge after PCI has been increasingly adopted and PCI

meet these contemporary demands and help us achieve better outcomes

has been expanded to centers without cardiothoracic surgical back

for our cardiovascular patients.

up.3,4 With these developments in care processes and improved
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outcomes, PCI is now in the early stages of being performed in non-

(e.g., cardiac anesthesiology, mechanical circulatory support, and car-

hospital outpatient facilities (e.g., ambulatory surgical centers [ASCs]).

diothoracic surgery) and that financial incentives (if any) for the physi-

While there are potential benefits to the performance of PCI in ASCs,

cian to perform the procedure at the ASC should be made clear to the

including cost-savings,5 wider access to care, a more gratifying patient

patient. Additionally, while catastrophic complications are expected to

experience, and greater physician autonomy, there are no published

be rare if case selection is appropriate, transfer protocols in the event

data on the safety of PCI performed in ASCs specifically. Hence, the

of a major complication should be clearly communicated to the care

true risk of adverse clinical outcomes in this setting is unknown,

team and the potential need for emergency transfer made clear to the

prompting concerns regarding quality and oversight.

patient prior to the procedure.

As a national society comprising over 4000 members of the inter-

As was clearly defined in SCAI's statement on ASC-based PCI

ventional cardiology community, SCAI is in a unique position to help

programs,6 certain standards for the facility itself, the equipment

define the quality benchmarks for the evaluation of catheterization

available at the ASC facility, and the qualifications of all personnel

laboratories and for the performance of PCI. In keeping with this role,

(e.g., nursing, technologist, and physician) practicing at the ASC were

SCAI in 2020 proactively generated and published two complemen-

felt to be of paramount importance. In particular, there was consider-

tary expert consensus statements detailing guidance for the optimal

able discussion regarding the use of intravascular imaging and physio-

performance of complex PCI as well as for the development of an

logic testing. Multiple studies have demonstrated improved outcomes

ASC-based PCI program.6,7 Notably, it was recommended that poten-

with the use of these strategies when compared with angiographically

tially high-risk procedures, such as the treatment of unprotected left

guided PCI alone.8–12 The availability of these technologies is neces-

main lesions, chronic total occlusions, and severely calcified lesions

sary to determine the need for revascularization and optimize PCI out-

be referred to a hospital-based setting.

6

Nevertheless, with the

comes. Nevertheless, given the lack of CMS reimbursement for

recent Centers for Medicare & Medicaid Services (CMS) decision all-

intravascular ultrasound and optical coherence tomography, there

owing for the reimbursement of complex PCI procedures in ASCs, a

was concern that monetary considerations could limit the use of these

growing (albeit small) number of atherectomy procedures are now

evidence-based tools in an ASC setting. As such, it was felt that SCAI

being performed in these centers. As such, a group of key opinion

needs to continue to actively advocate for additional CMS reimburse-

leaders from the interventional community, representing both physi-

ment for these adjunctive procedures, and assure their availability and

cians and industry partners, convened at the 2021 SCAI Virtual

use in ASC facilities, in order to promote best practices and decrease

Think Tank to deliberate how PCI in ASCs should be performed,

the potential for inappropriate PCI not only in ASCs, but in any PCI

especially when case selection falls outside of our initial recommen-

center.

dations, and the role that SCAI should play in optimizing quality in
these settings.

In order to ensure that ASCs performing PCI adhere to best practices, there was further consensus that some form of data monitoring

During the discussion, the overarching theme was related to the

would be necessary for ongoing quality assurance. In fact, since it is

importance of ensuring optimal outcomes for patients undergoing PCI

expected that the majority of PCIs performed at ASCs will and should

at ASCs (Figure 1). In the spirit of patient transparency, there was a

be lower risk, it was proposed that a higher benchmark for safety out-

strong sentiment that informed consent must include a clear acknowl-

comes should be considered. While existing national cardiovascular

edgement of the possible consequences of the absence of services

registries, such as the NCDR CathPCI registry, do provide a wealth of

and equipment that are normally present in a hospital-based setting

information regarding volumes, outcomes, and procedural appropriateness in the hospital setting, currently there is no existing registry
that evaluates metrics specific to an ASC site of service. Since the primary focus for monitoring ASCs would be to assess safety
(as opposed to a repository of data for research), it was agreed that
the development of a scaled-back registry, focused only on the essential measures of quality (including appropriate PCI, complication rates
and discharge protocols based on best practices), is needed and that
participation in such a registry should be tied to reimbursement in
order to guarantee ASC site involvement. The Outpatient Endovascular and Interventional Society (OEIS) is currently developing a
cardiac module within their national registry, specifically focused on
cardiac interventions performed at ASCs and outpatient interventional
suites and may provide an opportunity in the near future to implement a quality assessment program for ASCs performing PCIs. It was
recognized that the major barrier to implementing this process would

F I G U R E 1 Key recommendations for high-quality ASC-based PCI
program. ASC, ambulatory surgical centers; PCI, percutaneous
coronary intervention

be the cost involved and the need for a clinical director (e.g., cath lab
director) to provide physician and data oversight at the ASC, and it is
recommended that payers and ASC facilities take this into

5
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consideration when negotiating contracts and determining reimbursement policies for procedures performed in an ASC setting.

The Think Tank group agreed that SCAI should be involved in the
study of practice variation and valuation of devices related to peripheral

In summary, there was a general consensus that SCAI should con-

endovascular procedures. There was less agreement about how best to

tinue to advocate that ASCs abide by the expert recommendations laid

improve the quality of patient care and minimize costs. One barrier is the

out in the recent position statement, supplemented by the updated

identification of operators and institutions that are outliers, with respect

2021 Cath Lab Best Practices Consensus Document,13 on the perfor-

to quality and/or appropriateness of device utilization. It is not known

6

mance of PCI at an ASC. In order to preserve patient safety and ensure

how much practice variation should be expected, however. There was

high-quality outcomes, proper incentives to promote best practices (such

interest in joining resources with other physician groups and societies

as the use of intravascular imaging or physiology-guided PCI) and

(e.g. Society for Vascular Surgery) on policy statements to broaden global

requirements to engage in the reporting of quality metrics are needed.

impact of such initiatives. More generally, we should consider promoting

By working together with state and federal governing bodies and agen-

ethical business principles such as the value agenda, which in this con-

cies, SCAI has the opportunity to play a large and important role in the

text might include evaluation of practices based on the following param-

evolving landscape of ASCs performing PCI.

eters: (1) improved organization and integration of care, (2) established
measures to evaluate outcomes and cost of care, (3) process for bundled
payments for patient care cycles, (4) integrated care delivery across sepa-

3 | P E R I P H E R A L: UN D E R S T A N D I N G T H E
VALUE ASSESSMENT OF PERIPHERAL
TECHNOLOGIES IN ACUTE AND CHRONIC
INFRAINGUINAL INTERVENTIONS

rate facilities within a health care system, (5) expand or build services

The focus of the endovascular session was to discuss emerging issues

be to put quality assurance metrics in place, including peer review for

related to device selection for endovascular treatment of peripheral

appropriateness of PVIs, review of device selection and utilization,

artery disease, including critical limb ischemia. Stakeholders from the

and review of adherence to guidelines and expert consensus docu-

interventional cardiology community, industry, and SCAI leadership

ments. There was a debate about whether an outside review board

were in attendance. SCAI has a long history of prioritizing quality ini-

could assist with oversight and accountability for operators and insti-

tiatives regarding best practices and the appropriate use criteria in

tutions, and whether there should be reimbursement for such reviews.

across a geographic region to improve access to care, (6) lifecycle management with emphasis on value-based care, and (7) appropriate
reimbursement.
One option to identify “at risk” operators or laboratories would

14

The society has provided

There was moderate interest, but no consensus achieved, about how

several consensus guidelines (class of recommendation and level of

this could be financed and whether a SCAI-led, industry-funded mech-

evidence) for device selection in specific clinical or anatomic subsets,

anism could be put in place.

peripheral vascular interventions (PVI).

based on comparative device safety and effectiveness data.15,16 How-

Another option offered to address practice variation and under- or

ever, recent studies continue to show marked heterogeneity of treat-

overutilization of certain devices was organizing a peripheral laboratory

ment practices in real world settings, both when performed in hospital

certification or accreditation process through SCAI, which could certify

or at an ASC.17 The SCAI think tank provided a forum to discuss sev-

or accredit laboratories after a comprehensive peer-based review. SCAI

eral interrelated issues pertaining to SCAI's role in guiding hospitals

would provide guidance and issue accreditation to programs meeting

and clinicians regarding utilization of peripheral endovascular technol-

specific requirements, such as a random peer case review program and

ogies. It is hoped that standardization aligned with best practices will

QA/QI process. Accreditation for ASCs should not be based purely on

serve the wider community by minimizing disparities of care demo-

adjusted complication rates, but also on short- and long-term outcomes,

graphically and geographically.

as well as procedure and device appropriateness.

There was uniform support for SCAI's role in monitoring practice

There was general agreement that there should be awareness

patterns, device utilization, and outcomes in PVI. Given SCAI's man-

that proliferation of ASCs nationwide has occurred without proper

date to promote and enhance quality care and physician education,

professional societal quality/utilization/appropriateness evaluations in

these activities were deemed to be consistent with the mission of the

place. The office-based lab (OBL)/ASCs were not necessarily deemed

society. In addition, given SCAI's prior quality initiatives in publishing

to be the problem, and in fact, many patients seem to prefer to

expert consensus statements and appropriateness criteria, there is

receive care in an OBL/ASC setting. However, the current financial

precedent and expertise for these initiatives within the SCAI member-

incentives of OBL/ASC physicians and lack of oversight regarding

ship. Past lessons from highly publicized examples of rarely appropri-

appropriateness of procedures and device selection pose a potential

ate PCIs highlight the legal exposure to physicians and health care

concern. One topic, which was debated, was whether OBL/ASCs per-

systems as well as the negative impact such cases can have on the

forming endovascular procedures should be required to be part of a

reputation of the interventional cardiology community. For these rea-

PVI registry. Physicians in attendance and stakeholders from industry

sons, it was agreed that SCAI, physician membership, and industry

were keenly interested in a concept of a comprehensive registry that

partners should be aligned in fostering transparency regarding prac-

would include data on costs, procedural complications/outcomes, and

tice patterns with an eye toward understanding and disseminating

patient reported short- and long-term outcomes. Mandatory participa-

best practice guidance to the peripheral interventional community.

tion would be necessary for full engagement, complete quality

6
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metrics, and accountability. However, the feasibility of such a registry
for ASCs might be limited since outpatient-based laboratories do not

TABLE 1

Practice variation in device selection in PVI procedures

Practice variation in peripheral vascular interventions (PVI)

generally have an infrastructure for data collection, as already discussed in the coronary section above. Whether self-reported patient
data would be accurate and impactful was also discussed.
Another central topic discussed was whether observational/registry data would change physician practice patterns. There was moderate pessimism that such data would impact practice patterns since, for
instance, even high-quality randomized controlled trials have not

Lessons learned and emerging
challenges

Potential societal initiatives and
solutions

•PVI and device selection can
be affected by financial
incentives

•Expanded local and national
peer review board/system

•Financial incentives can lead
to:

•SCAI-led industry funded
peripheral laboratory
certification and/or
accreditation for OBL/ASCs.

•Unnecessary procedures,
adverse outcomes, and
harm to patients

•Establish a comprehensive
outpatient PVI registry, with
participation being linked to
reimbursement

•Healthcare disparities

•Realignment of financial
incentives to emphasize
evidence-based and outcomesbased metrics

•Additional expense to
payers and health care
systems

•Engagement with other
physician groups and vascular
societies

resulted in large-scale utilization of drug-coated balloons. There was
consensus that given the strong influence of reimbursement on physician behavior, SCAI members and industry should strive to work with
payers to realign payment structure, with an emphasis on evidencedbased outcomes-based metrics. There was a view that consensus documents may not help to change physician behavior unless they can be
enforced. Thus, linking registry participation to reimbursement by
payers was discussed.
In summary, there was general agreement that issues related to
PVI procedural appropriateness, heterogeneity in device selection,
variance in cost and practice patterns were all linked in complex ways
and are important priorities for SCAI to be engaged in (Table 1). The
expansion of OBL/ASCs was recognized as an opportunity to create
SCAI-led quality assurance metrics, such as peer review for appropriateness of PVI and review of device selection/utilization. Several
options, such as development of a SCAI-led certification or accreditation process for operators and laboratories and participation in PVI
registries were identified as discussed above. There was a consensus
that SCAI should advocate for realignment of financial incentives with

•Patient and societal mistrust
•Identifying “at risk” operators/
outliers is challenging
•OBL/ASCs expansion is
occurring without a
mechanism to evaluate
appropriateness, quality, and
safety
•Consensus/guideline
documents are not being
followed and do not lead to
higher quality care

an emphasis on outcomes-based metrics.

4 | STRUCTURAL: ENHANCING
I N N OV A T I ON I N STR U C TU RA L H E A R T
P R O C E D U RE S— E M E RG I N G I ND I C A T I O N S
FOR VALVES, CLIPS, AND PLUGS
As more cardiovascular patients survive to an advanced age, with inherent associated comorbidities including frailty, cardiac procedures will

•Physician behavior is strongly
linked to reimbursement
•Reimbursement is not
necessarily linked to best PVI
practices
Abbreviations: ASC, ambulatory surgical centers; OBL, office-based lab;
SCAI, society for cardiovascular angiography and interventions.

need to continue to evolve to treat diseases via percutaneous (rather
than open surgical) methods. The current era of minimally invasive

perform transcatheter mitral valve replacement (TMVR). While such

devices for structural heart disease (SHD) interventions presents clini-

“off-label” use of a product may gain traction within the interven-

cians with a toolbox to develop creative solutions. As expected, these

tional cardiology community through podium presentations, case

solutions involve permutations of utilizing medical devices in methods

reports, and social media,19 a presentation bias occurs as operators

novel to their intended purpose, or in the United States device regula-

are reluctant to share deaths or serious complications. Thus, quality

tory framework, outside of their approved “labeled” indication.

and safety remain a concern regarding appropriate case section, tech-

For example, transcatheter valves are approved for transcatheter

nical skillsets, complication management, and post-procedure care. In

aortic valve replacement (TAVR) in patients with severe aortic steno-

addition, the medical device industry, charged with assuring proper

sis. However, there are complex patients for whom adjunctive proce-

use of their products through operator training, support, and guid-

dures have evolved to overcome challenges to successfully

ance, are unable to assist to assure optimal procedural outcomes

performing TAVR that are not part of the food and drug administra-

when the devices are used off-label. While measurement and commu-

tion (FDA) labeling for the procedure (e.g., BASILICA).

18

Furthermore,

nication of quality within the interventional community and to the

given that there are no similar valves approved for replacement of the

public remains a challenge already for FDA-approved procedures, it is

mitral valve, operators have utilized the available aortic valves to

exceedingly difficult for off-label device procedures.
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The specialty of interventional cardiology has historically been

expand indications and procedures (e.g., TAVR in patients with mod-

at the forefront of innovation and improved patient care by generat-

erate aortic stenosis) as has been the current and accepted stan-

ing the data to support novel procedures (e.g., randomized con-

dard. However, leaflet altering procedures such as BASILICA

trolled trials, well-conducted observational studies). Furthermore,

preceding TAVR would not require such randomized trial data to

carefully designed registries are used to examine off-label device

become “on-label” for appropriate patients. Furthermore, single arm

use and supplements the research on approved products beyond the

studies and appropriate registry data would be large enough to

randomized data.20,21 To date, these innovations have principally

develop standards for patient outcomes that should be acceptable

been in the areas of coronary and peripheral vascular procedures,

for such procedures. Lastly, reimbursement for these procedures

however. Notably, and in contrast, the field of SHD has developed

continues to be an issue for operators, and SCAI would be appropri-

with unique challenges that necessitate a different pathway for

ately empowered with this type of data to pursue opportunities to

meeting deficiencies in patient/procedural care. These include

appropriately affect reimbursement and payment decisions.

(1) The mandate of the “Heart Team” approach with the physical
presence of both cardiac surgeons and interventional cardiologists
to evaluate and treat patients cooperatively; and (2) National Cover-

4.2

Organization of education and training

|

age Decisions that closely associate FDA labeling of devices, clinical
trial data, and reimbursement for structural heart procedures. In

Education and training are ongoing needs with continued proce-

essence, enhancing treatment for patients with SHD now involves

dural innovations and SCAI is ideally suited to fulfill this need. Pre-

the complexity of the medical device industry, federal government,

viously,

cardiac surgery, and interventional cardiology. The mission of SCAI

requirement statements and supported e-book learning for inter-

is to lead the global interventional cardiology community in educa-

ventional procedures. All of these avenues should be considered

tion, advocacy, research, and quality of patient care. Clearly, to

for training in the structural heart arena with a focus on adapting

achieve all of these aims, SCAI must endeavor to enhance and

the best available media and computing resources to support train-

improve the treatment of patients with SHD moving forward.

ing programs. Likewise, there is a need for “expert consultative”

SCAI

has

developed

position

statements,

training

services in which “experts” in the field could be consulted for procedural advice prior to an operator taking on an advanced proce-

4.1 | Alignment of operators, industry, and
regulators

dure. These could be facilitated by SCAI by organizing and
publicizing an available “expert panel” of individuals agreeable to
providing such a service as well as by providing the optimal

To allow iterative expansion of labeled indications for devices

method of communication between parties. The concept of “virtual

and/or procedures, SCAI has the unique ability to unite operators,

proctoring” was also brought forward given the rapid development

the medical device industry, and the FDA to devise acceptable next

in hardware and software (e.g., augmented reality and virtual real-

steps to achieve this result (Figure 2). SCAI think tank consensus

ity) to allow such interactions currently and in the near future,

was to consider single-arm studies and more specific device/proce-

although there are multiple potential liability concerns that would

dure registry data that could be utilized for this goal and SCAI could

have to be considered prior to implementation.

be the organizing “sponsor” to facilitate the process. In this way,
multicenter industry sponsored studies would still be undertaken to

4.3

|

Partnership with congenital interventionalists

It was recognized that a great deal of symmetry exists between these
structural heart treatment issues proposed and those faced by our
colleagues in the CHD arena. Thus, moving forward, the proposed
efforts by SCAI should not occur specifically to the structural heart
arena or specific procedures, but rather be developed as more general
templates and pathways to allow for iterative expansion of
indications.
To summarize, clearly innovation and meeting the needs of an
aging population require that our tools and techniques expand significantly in the structural heart space. Alignment of relevant stakeholders and agreement on a process to facilitate appropriate FDA
F I G U R E 2 SCAI as the intermediary to align structural operators,
the medical industry, and the food and drug administration. SCAI,
society for cardiovascular angiography and interventions

approvals, potentially orchestrated by SCAI, together with organization of novel educational and training initiatives, will all be pivotal to
expand treatment options in a safe and efficacious manner.
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5 | C O N GE N I TA L : H O W C A N T H E
P E D I A T R I C I N T E R V E N T I O N A L CO M M U N I T Y
E F F EC TI V EL Y TR A CK I M P L A N TA B LE
D E V I C E S F R O M C H I L DH O O D T O
ADULTHOOD?
At the CHD Think Tank discussion, members of the pediatric/

T A B L E 2 Summary of tracking of implantable devices in CHD:
gaps and strategies for improvement
Tracking of implantable devices from childhood to adulthood

Gaps
•No tracking system
currently available

•Prioritization of certain devices for
tracking throughout the lifetime of
CHD patients

•Industry tracks devices only
if FDA mandated

•Backfilling into currently available
registries and device-tracking
systems within industry

•Tracking can only occur if
device registration is
submitted

•Develop a system to track off-label
use of devices

•Lack of active surveillance

•Establishment of a SCAI registry
specifically for device tracking for
CHD patients

•Off-label use of devices for
CHD prevents tracking

•Partnering with EMR systems to
develop electronic device
registration and tracking
algorithms

•Transition of care is not
streamlined into
adulthood

•Development of patient specific,
health passports

•Gaps in transfer of EMR
between hospital systems

•Regulatory agencies/insurance
carriers to mandate device
registration/tracking

congenital interventional cardiology community met with corporate representatives of CHD device manufacturers and discussed
the current status of device-tracking from childhood into adult
life, identified gaps in this process, and offered possible strategies
and solutions to fill these gaps. The discussion revolved around
how SCAI can engage the various stakeholders including physicians, industry, and patients together to establish an improved
system for device tracking.
Survival of children born with CHD into adulthood has steadily
improved over the past three decades.22 This has brought about several new challenges in the management of adult survivors of CHD.
One of these involves tracking of devices implanted during infancy
and childhood into adult life. Tracking poses unique challenges, as
infants and children who are treated can now outlive the physicians
implanting the devices, device-tracking registries, the manufacturer,
and even currently available technology. Further, CHD patients often
require reoperations where devices may be explanted or modified.
Repeat interventions may also alter the original implanted device or
additional devices may be implanted superimposed onto previously
implanted devices. Clearly, then, details of the type, medical device
manufacturer, model, size, and number of devices implanted previously, along with the implant dates, procedure notes, and potential
procedural challenges encountered are vital for the proper transfer

Strategies to streamline device
tracking

•Complexities in allowing
patient access to medical
records
Abbreviations: CHD, congenital heart disease; EMR, electronic medical
records.

and continued care of pediatric CHD patients transitioning to adult
care. However, this effort will require a standardized device tracking

are registered, and tracking is dependent on the operator to submit

mechanism, collaboration of all stakeholders, and addressing of con-

the device registration information. Furthermore, industry has no

cerns over potential HIPAA violations to enable proper transfer of

standardized methods of tracking of devices used off-label, which is a

information.

common practice across the CHD interventional community. The FDA
also does not require all implantable devices to be registered. For
example, there is no requirement to register stents, which are often

5.1 | Gaps in the current device-tracking practices
for CHD patients

used for treatment of vascular stenoses in CHD. Moreover, follow-up
for CHD patients is frequently not streamlined during the transition
to adult congenital cardiology care.

There are no standardized tracking systems currently available for

Most hospitals typically have an internal device-tracking system

devices implanted to treat CHDs and the gaps are multifactorial

for patients within the health care system. Currently, most electronic

(Table 2). Industry tracks certain devices as mandated by the FDA,

medical records (EMR) are not built with any robust device-tracking

which include devices that have the potential to result in a serious

platform. In addition, the EMRs of distinct hospital systems most typi-

adverse health consequence in the event of a device failure, are

cally do not communicate with each other. Therefore, as pediatric

implanted for more than one year, and whenever the device is

patients' age and move out of parental care and insurance, details of

intended to be a life sustaining or life supporting device outside of a

their implanted devices are often lost. National registries such as the

hospital setting (e.g., implantable pacemakers).23,24 However, this pro-

NCDR (National Cardiovascular Data Registry), and the CCISC

cess is not universally applied to all permanently implantable medical

(Congenital Cardiovascular Interventional Study Consortium) are nei-

devices (e.g., vascular stents and plugs) and active surveillance in some

ther built specifically for device-tracking, nor are they kept active or

cases. In addition, when it does occur, the tracking process is typically

updated regarding long-term device related issues such as late device

not beyond a few years post-implant. One of the pitfalls for industry

malfunction, device explantation, device reintervention, or change in

tracking devices is that the company can track only those devices that

the patient's clinical situation.24–26
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There are two other gaps in the mechanisms for transfer of medi-

retrospective data that can be used to gain eventual FDA approval for

cal records—the patient having personal access to their medical

the off-label indication to treat CHD as well as to develop proper CPT

records in a passport-like file so that they can easily transmit it to a

codes and valuation for the procedure.

new physician without requiring institution to institution transfer of

Compliance to register an implanted device can be a challenge.

medical records, and a registry system to contain this passport. This is

However, strategies involving regulatory agencies and insurance car-

much more complicated, obviously, and risks breaches in privacy.

riers to mandate registration of implanted devices by the hospital or
implanter prior to reimbursement can improve compliance. Some of
these rules are already in practice for SHD. Alliance with insurance

5.2 | Strategies for SCAI to develop a streamlined
device tracking process for CHD patients

carriers could also ensure reputation incentives for transparent, selfreporting, and improved ratings for hospitals to participate in device
tracking registries.

There exists a great opportunity for SCAI to engage physicians, indus-

In summary, the SCAI CHD Think Tank group of CHD physicians

try partners, regulatory bodies, and insurance carriers to develop a

and industry representatives had a very fruitful discussion regarding

simple, easy to use, and streamlined device tracking system for

tracking of devices throughout the lifetime of patients with CHD.

patients with CHD that can be updated periodically with follow-up

There was group consensus that there is a need for establishing a sim-

patient and device related data while ensuring that patient privacy is

ple pathway for continuous tracking of these devices. There exists a

protected. The following points were made during the group discus-

great opportunity for SCAI to engage physicians, industry partners,

sion and summarized in (Table 2):

regulatory bodies, and insurance carriers to develop a robust devicetracking system not just for CHD, but for other types of interventional

1. There is common agreement among the stakeholders of the importance of tracking devices used to treat CHD.
2. The CHD and industry representatives are enthusiastic to engage
and collaborate with SCAI in developing a process for device track-

cardiovascular procedures with permanent implants. SCAI has an
opportunity to play an important role and can have a significant
impact in the progress of interventional therapies by tracking of medical devices for patients with CHD.

ing throughout the lifetime of children born with CHDs.
3. Specific strategies for device tracking can include but are not limited to:

6

|

CONC LU SION

a. Prioritization of implantable devices for tracking throughout the

SCAI is committed to enhancing safety, quality, and efficacy of percuta-

lifetime of the CHD patient, depending on long-term complica-

neous procedures. The current topics highlight areas of growth within

tions, impact on future surgeries or other medical care (i.e., MRI

our field, including the move to ambulatory surgical centers, providing

compatibility of certain devices).

more uniformity and standardization of care across geographies and

b. Backfilling of missing patient and device related information into

demographics, following our pediatric congenital patients as they age

currently available registries and device-tracking systems within

and move through life, and rapidly evolving technology and techniques

the device industry.

in the structural arena to meet the needs of a diverse, aging population.

c. Develop a system to track off-label use of devices.

Hopefully, this initial discussion fuels attempts at collaboration to meet

d. Establishment of a national registry by SCAI specifically for CHD

these challenges, and we welcome any further discussion from impor-

device tracking which includes tracking of multiple device implants,

tant stakeholders and the wider cardiovascular community.

explants, and device reinterventions in a single patient.
e. Partnering with EMR systems to develop electronic device registration and tracking algorithms for implantable devices, which
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